Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node

Archives of Surgery

Volumn 145, Issue 6, 2010, Pages 564-569

  Yegiyants, Sara ^a   Romero, Lina M ^a   Haigh, Philip I ^a   DiFronzo, L Andrew ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DISTANT METASTASIS; HISTOPATHOLOGY; HUMAN; IRRADIATION; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; MICROMETASTASIS; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, TEACHING; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNNECESSARY PROCEDURES;

EID: 77953843434     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2010.84     Document Type: Article

References (43)

1. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222(3):394-399.
2. Temple LK, Baron R, Cody HS III, et al. Sensory morbidity after sentinel lymph node biopsy and axillary dissection: a prospective study of 233 women. Ann Surg Oncol. 2002;9(7):654-662.
3. Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23(19):4312-4321.
4. Fallowfield LJ, Jenkins VA, Johnson L, et al. Impact of sentinel node biopsy on quality of life in the ALMANAC trial. Breast Cancer Res Treat. 2004;88:S77.
5. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol. 2002;20(17): 3628-3636.
6. Kim T, Giuliano A, Lyman GH, et al. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a meta-analysis. Cancer. 2006;106(1):4-16.
7. Lyman GH, Giuliano AE, Somerfield MR, et al; American Society of Clinical Oncology. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703-7720.
8. Fant JS, Grant MD, Knox SM, et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol. 2003;10(2):126-130.
9. Guenther JM, Hansen NM, DiFronzo LA, et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg. 2003;138(1):52-56. (Pubitemid 36055648)
10. Hwang RF, Gonzalez-Angulo AM, Yi M, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110(4):723-730.
11. Langer I, Marti WR, Guller U, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: a prospective analysis of 150 patients after SLN biopsy. Ann Surg. 2005;241(1):152-158.
12. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140-1151.
13. McCready DR, Yong WS, Ng AK, Miller N, Done S, Youngson B. Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false-negative rates. J Natl Cancer Inst. 2004;96(11):873-875. (Pubitemid 38807608)
14. Turner RR, Chu KU, Qi K, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000;89(3):574-581.
15. Weiser MR, Montgomery LL, Tan LK, et al. Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol. 2001;8(2):145-149.
16. Kamath VJ, Giuliano R, Dauway EL, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg. 2001;136(6):688-692.
17. Rahusen FD, Torrenga H, Van Diest PJ, et al. Predictive factors for metastatic involvement of nonsentinel nodes in patients with breast cancer. Arch Surg. 2001;136(9):1059-1063. (Pubitemid 32982998)
18. Wong SL, Edwards MJ, Chao C, et al; University of Louisville Breast Cancer Sentinel Lymph Node Study Group. Predicting the status of the nonsentinel axillary nodes: a multicenter study. Arch Surg. 2001;136(5):563-568.
19. Haagensen CD. Diseases of the Breast. New York, New York: Saunders; 1986:911-913.
20. Fisher B, Redmond C, Fisher E, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomywith or without radiation. N Engl J Med. 1985;312(11):674-681. (Pubitemid 15134703)
21. Fowble B, Solin LJ, Schultz DJ, Goodman RL. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys. 1989;17(4):703-710. (Pubitemid 19250521)
22. Veronesi U, Salvadori B, Luini A, et al. Conservative treatment of early breast cancer: long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy. Ann Surg. 1990;211(3):250-259.
23. Siegel BM, Mayzel KA, Love SM. Level I and II axillary dissection in the treatment of early-stage breast cancer: an analysis of 259 consecutive patients. Arch Surg. 1990;125(9):1144-1147.
24. Recht A, Pierce SM, Abner A, et al. Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol. 1991;9(6):988-996.
25. Halverson KJ, Taylor ME, Perez CA, et al. Regional nodal management and patterns of failure following conservative surgery and radiation therapy for stage I and II breast cancer. Int J Radiat Oncol Biol Phys. 1993;26(4):593-599.
26. Chua B, Ung O, Boyages J. Competing considerations in regional nodal treatment for early breast cancer. Breast J. 2002;8(1):15-22.
27. Louis-Sylvestre C, Clough K, Asselain B, et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? results of a randomized study with 15 years of follow up. J Clin Oncol. 2004;22(1):97-101.
28. Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: A follow-up study of 4008 procedures. Ann Surg. 2004;240(3):462-468.
29. Furukawa T, Kubota T, Tanino H, et al. Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Res. 2000;20(5C):3657-3658.
30. Lenert JT, Vlastos G, Mirza NQ, et al. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol. 1999;6(8):762-767.
31. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997; 15(7):2483-2493.
32. Sarvi M, Mehta P, Vallow L, et al. Is nodal irradiation necessary in breast cancer patients with positive sentinel node biopsy without axillary dissection. Int J Radiat Oncol Biol Phys. 2002;54(2):232-233.
33. Pejavar S, Wilson LD, Haffty BG. Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 2006;66(5):1320-1327.
34. Gadd M, Harris J, Taghian A, et al. Prospective study of axillary radiation without axillary dissection for breast cancer patients with a positive sentinel node. Paper presented at: Annual San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, Texas. Abstract 22.
35. de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer. 1992;66(3):523-527.
36. Nasser IA, Lee AK, Bosari S, Saganich R, Heatley G, Silverman ML. Occult axillary lymph node metastases in "node-negative" breast carcinoma. Hum Pathol. 1993;24(9):950-957.
37. Pickren JW. Significance of occult metastases: A study of breast cancer. Cancer. 1961;14:1266-1271.
38. Rosen PP, Saigo PE, Braun DW Jr, Beattie EJ Jr, Kinne DW. Occult axillary lymph node metastases from breast cancers with intramammary lymphatic tumor emboli. Am J Surg Pathol. 1982;6(7):639-641.
39. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer. 1978;42(4):2025-2031. (Pubitemid 9055971)
40. Trojani M, de Mascarel I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of breast: Detection by immunohistochemistry and prognostic significance. Br J Cancer. 1987;55(3):303-306. (Pubitemid 17036845)
41. Hainsworth PJ, Tjandra JJ, Stillwell RG, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg. 1993;80(4):459-463. (Pubitemid 23116083)
42. McGuckin MA, Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer. 1996;73(1):88-95. (Pubitemid 26026266)
43. Cote RJ, Peterson HF, Chaiwun B, et al; International Breast Cancer Study Group. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. Lancet. 1999;354(9182):896-900.